Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
- 27 April 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (6) , 1649-1659
Abstract
Background and Aims: Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results: We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions: Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.Keywords
This publication has 34 references indexed in Scilit:
- A disparity of words: racial differences in oncologist–patient communication about clinical trialsHealth Expectations, 2013
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJournal of Hepatology, 2013
- Implicit Stereotyping and Medical Decisions: Unconscious Stereotype Activation in Practitioners' Thoughts About African AmericansAmerican Journal of Public Health, 2012
- Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology GroupAnnals of Surgical Oncology, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Physician Implicit Attitudes and Stereotypes About Race and Quality of Medical CareMedical Care, 2008
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007
- Prospective validation of the Barcelona Clinic Liver Cancer staging systemJournal of Hepatology, 2006
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994